By Bruce K. Brown, Ph.D.,Thermo Fisher Scientific
Despite the public attention and large population impacted by HIV, developing a cure has been particularly difficult. To successfully cure an infected individual the virus would need to be fully eradicated from their body, which is difficult because HIV is extraordinarily good at hiding in a person’s cells. Anti-retroviral therapy (ART) drugs have been very effective at keeping viral infection below detection limits, but the drugs cannot reach these hiding places, or “latent reservoirs.”
A client was exploring the possibility of re-purposing an internal collection of antifungal CYP51A1 inhibitors for targeting cancers. GVK BIO was commissioned to enable the such project. Learn how a CYP51A1 inhibitor screening assay using the RapidFire HTMS method was deemed to be optimized, and screening of client compounds was enabled with an acceptable throughput and in a cost-effective manner.